The Drug Security Forum
will be held on the opening day of the St. Petersburg International Economic
Forum. Its business programme will include expert discussions on the Russian
pharmaceutical industry’s growth strategies and the role of those strategies in
ensuring national drug security.
The COVID-19 pandemic
has highlighted the issue of national drug security and has given a new
perspective to the development strategies of the Russian pharmaceutical
industry. Import independence and innovation are key to strengthening Russia’s
pharmaceutical industry. The country must also develop a domestic active
pharmaceutical ingredient (API) manufacturing network and create conditions
that foster innovation in the Russian pharmaceutical industry. Not only will
supporting domestic pharmaceutical lifecycle management and shifting the
regulatory focus from expanding generic product portfolios to launching a
complete range of domestic innovative preparations bolster national drug
security, it will also increase the competitiveness of the Russian
pharmaceutical industry, raising it to the rank of global market leader.
“The pharmaceutical
industry support measures implemented in the Russian Federation over the last
several years have taken operations to the next level. The Russian
pharmaceutical industry has proven that it can operate effectively and without
interruptions, even during a pandemic. The drugs that we are developing and
manufacturing are not only satisfying domestic market demand, they are also
showing promising export potential,” said Aleksander Petrov, Chairman of the
Subcommittee on the Circulation of Medicines and Pharmaceutical and Medical
Industry Development, part of the Committee on Health Protection of the State
Duma of the Russian Federation.
Participants of the
session ‘Growth Strategy of the Russian Pharma Industry as a Basis of National
Drug Security’, will discuss the regulatory solutions and government
incentives Russia needs to create a new, competitive API manufacturing
industry, the government support and regulatory instruments with the potential
to stimulate innovation in the Russian pharmaceutical industry, and other
development measures the national pharmaceutical industry could use to address
expanding access to and the variety of available medicines, drug list planning,
deficit prevention, and other topical issues.
The
Drug Security Forum is organized by the Roscongress Foundation and the Content
Foundation for Expertise and Analysis. The Forum is organized with the support
of the Ministry of Health of the Russian Federation and the Subcommittee on the
Circulation of Medicines and Pharmaceutical and Medical Industry Development,
part of the Committee on Health Protection of the State Duma of the Russian
Federation.
The
session is held with the support of Pharmasyntez Group.
Official Drug Security Forum website: pharmforum.org
Roscongress Foundation is providing the Russian and international business an opportunity to place company’s business card in a format of a short video on the RCBusiness platform. We invite you to offer your goods and services, find investors, peers and partners, enlarge the market and supply chain, establish new companies and join existing projects.
We have set up the platform forbusiness.roscongress.org to cater the needs of professionals representing a wide variety of economic sectors and to present the opportunities of your business to a large community of Russian and international companies,
Step 1. Please сreate a video business card about your company and your product(s) / services;
Step 2. Search the site under the sub-sections For Sale / To Buy / Opportunities to Partner / Investment project / Financial Services / Solutions.
Step 3. Receive feedback directly or through RC intermediaries.
Enlarge your business together with RCBusiness.
By publishing content on this website, you give the Foundation the non-exclusive right (a regular non-exclusive license) to use this content and the intellectual property contained therein under the following conditions: in perpetuity, without renumeration, without the need to obtain additional permission from the user to use these objects, for use in all countries around the world; to use in any way in any media – both with and without reference to the author(s); with the right to grant rights to third parties; in the Foundation’s pursuit of its legal rights and interests, as well as in pursuit of marketing goals and in marketing materials, as part of the Foundation’s commercial projects and services, including publication on other internet resources, with the right to grant third parties the right to use these objects. The Foundation reserves the right to save archived copies of the content and to refuse to withdraw marketing materials containing this information from circulation.
By publishing information on this website, you also grant third parties the right to use this content and the intellectual property contained therein, under a limited license, with the intent of viewing the content for information purposes.
Without the express permission of the Foundation, the use (including, but not limited to: database access, collection, recording, systematization, transmission, distribution, copy, and reproduction) of content (including, but not limited to: images, photographs, videos, user contact information, and other elements) and objects that the Foundation has the exclusive rights to, using any methods, for any goals not laid out in these terms and conditions (e.g., for creating a database or including in an existing database, distribution in third-party information systems, irrelevant calls to users) is prohibited, regardless of volume or the consent of individual users. None of the objects to which the Foundation has exclusive rights, including content elements and information about website users, published on this website can be used in any way that is prohibited by our terms and conditions without the advance express permission of the Foundation.
The Foundation reserves the right to limit the publication of information (including images, photographs, videos, user contact information, and other elements) by users of the website at its discretion and without explanation.
The user hereby, of their own free will and in their own interests, by inputting their personal data in the personal web office of the website forbusiness.roscongress.org, consents to the processing of their personal data, given during registration, by the Roscongress Foundation (registered at 1101, entrance 7, 12, Krasnopresnenskaya nab., Moscow, 123610, Russia) under the following conditions:
Personal data is processed automatically.
Consent is given to process the following personal data: surname, name, patronymic, sex, date and place of birth, passport information (citizenship, series and passport number, home and mobile telephone numbers, information about place of work or study, photograph.
The purpose of personal data processing is to enable:
During the processing of personal data, the following actions will be completed: collection, recording, verification, systematization, accumulation, storage, clarification (updating or amendment), retrieval, use, transfer (distribution, provision, access), anonymization, blocking, deletion, and destruction of data.
The transfer of personal data to third parties will take place under the regulations set out in the law of the Russian Federation, and according to the agreement concluded with the involvement of the user or with the agreement of the user.
This agreement will be valid for an indefinite period, and may be rescinded by the user if he or she gives notice in writing to the Roscongress Foundation in accordance with the regulations set out in the law of the Russian Federation.
The Roscongress Foundation will cease processing of personal data and destroy it within 1 (one) month of receiving a request to cancel this agreement, or within the period specified by current legislation if the agreement is not rescinded. From the moment the Roscongress Foundation receives notice that the agreement to process personal data is to be rescinded, the right to enter the Event site will also be rescinded.